Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Uma Kher"'
Autor:
Jason J. Z. Liao, Mohammed Z.H. Farooqui, Junya Kuroda, Morio Matsumoto, Kazutaka Sunami, Hiroshi Kosugi, Uma Kher, Dai Maruyama, Kenshi Suzuki, Kensei Tobinai, Yasuhiro Koh, Takashi Shimamoto, Kiyoshi Ando, Patricia Marinello, Kenji Matsuda, Shinsuke Iida, Masafumi Taniwaki
Publikováno v:
International Journal of Hematology. 113:777-784
The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed or refractory multiple my
Autor:
Zev A. Wainberg, Kohei Shitara, Eric Van Cutsem, Lucjan Wyrwicz, Keun Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Cheol Chung, Jeeyun Lee, Hugo Raul Castro-Salguero, Wasat Mansoor, Maria Ignez Braghiroli, Nina Karaseva, Eray Goekkurt, Hironaga Satake, Joseph Chao, Uma Kher, Sukrut Shah, Pooja Bhagia, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 40:243-243
243 Background: KEYNOTE-062 (NCT02494583) is a global phase 3 study of pembrolizumab (pembro) as monotherapy and in combination with chemotherapy (chemo) versus chemo as first-line therapy for PD-L1–positive (combined positive score [CPS] ≥1) adv
Autor:
Sukrut Shah, Chie Schin Shih, Zev A. Wainberg, Kohei Shitara, Joseph Chao, Salah-Eddin Al-Batran, Kensei Yamaguchi, Marcelo Garrido, Eniko Varga, Peter C. Thuss-Patience, Josep Tabernero, Eric Van Cutsem, Uma Kher, Yung-Jue Bang, Charles S. Fuchs, Hyun Cheol Chung, Daniel Hochhauser, Pooja Bhagia, Kei Muro, Jen-Shi Chen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(7)
Purpose: Pembrolizumab demonstrated efficacy in PD-L1–positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (G/GEJ) cancer in the first-, second-, and third-line setting in KEYNOTE-062, KEYNOTE-061, and KEYNOTE-05
Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
Autor:
Joseph Chao, Maria Ignez Braghiroli, Charles S. Fuchs, Y-J. Bang, Sukrut Shah, Eray Goekkurt, E. Van Cutsem, J. Tabernero, Iveta Kudaba, H.C. Chung, Hugo Castro, Uma Kher, Wasat Mansoor, Zev A. Wainberg, Lucjan Wyrwicz, K.-W. Lee, K. Shitara, Marcelo Garrido
Publikováno v:
Annals of Oncology. 30:ix43-ix44
Autor:
Daniel Isaza, Craig J. Reist, KyungAh Im, Jennifer A. White, Andrew M. Tershakovec, Robert P. Giugliano, Eugene Braunwald, Michael A. Blazing, Christopher P. Cannon, Mikael Dellborg, Erin A. Bohula, Sabina A. Murphy, Uma Kher, Yuliya Lokhnygina, Jose Lopez-Sendon
Publikováno v:
Journal of the American College of Cardiology. 67(4):353-361
Background Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) significantly reduced the first primary endpoint (PEP) in patients post-a
Autor:
Nina A. Karaseva, Sukrut Shah, Lucjan Wyrwicz, Joseph Chao, Christian Caglevic, Kohei Shitara, Luis Villanueva, Eric Van Cutsem, Al B. Benson, Eray Goekkurt, Wasat Mansoor, Marcelo Garrido, Iveta Kudaba, Keun Wook Lee, Jeeyun Lee, Maria Alsina, Andrew H. Ko, Charles S. Fuchs, S. Peter Kang, Josep Tabernero, Hugo Castro, Hironaga Satake, Uma Kher, Yung-Jue Bang, Maria Ignez Braghiroli, Peter C. Enzinger, Zev A. Wainberg, Hyun Cheol Chung
Publikováno v:
JAMA Oncology. 6:1571
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alo
Autor:
Marcelo Garrido, Salah-Eddin Al-Batran, Sukrut Shah, Pooja Bhagia, Kensei Yamaguchi, Peter C. Thuss-Patience, Eniko Varga, Eric Van Cutsem, Charles S. Fuchs, Kohei Shitara, Chie-Schin Shih, Daniel Hochhauser, Uma Kher, Joseph Chao, Zev A. Wainberg, Jen-Shi Chen, Kei Muro, Yung-Jue Bang, Hyun Cheol Chung, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 38:427-427
427 Background: Pts with advanced gastric/gastroesophageal junction (G/GEJ) cancer received pembro monotherapy (200 mg Q3W) 3L+ in cohort 1 of KEYNOTE-059 (NCT02335411), 2L in KEYNOTE-061 (NCT02370498), or 1L in KEYNOTE-062 (NCT02494583). We present
Autor:
Marcelo Garrido, Lucjan Wyrwicz, Charles S. Fuchs, Soonmo Peter Kang, Y.-J. Bang, Sukrut Shah, Eray Goekkurt, J. Tabernero, H. Cheol Chung, K. Shitara, Maria Ignez Braghiroli, Hugo Castro, E. Van Cutsem, Zev A. Wainberg, K.-W. Lee, Joseph Chao, Wasat Mansoor, Uma Kher, Iveta Kudaba
Publikováno v:
Annals of Oncology. 30:v878-v879
Background KEYNOTE-062 (NCT02494583) was a randomized, study of 1L pembrolizumab (P) or pembro + chemo (P+C) vs chemo (C) in patients (pts) with PD-L1 combined positive score ≥1 (CPS ≥1), HER2-negative, advanced GC. Methods Eligible pts were rand
Autor:
Maria Ignez Braghiroli, Soonmo Peter Kang, Lucjan Wyrwicz, Joseph Chao, Eray Goekkurt, Marcelo Garrido, Y-J. Bang, K. Shitara, E. Van Cutsem, Iveta Kudaba, Wasat Mansoor, K.-W. Lee, H. Castro Salguero, H.C. Chung, Uma Kher, J. Tabernero, Charles S. Fuchs, Zev A. Wainberg, Sukrut Shah
Publikováno v:
Annals of Oncology. 30:iv152-iv153
Autor:
Eliot A. Brinton, Antonio M. Gotto, Jennifer Moon, Philip J. Barter, Uma Kher, Sukrut Shah, Manash Shankar Chatterjee, Yang Liu, Christopher P. Cannon, Yale B. Mitchel, Xiujiang Susie Li, Sanskruti Vaidya, Hayes M. Dansky
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 19:543-549
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has previously been shown to reduce low-density lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C) in patients with or at high risk of coron